Dr. Landgren on the Clinical Impact of KRd-D in Multiple Myeloma
May 13th 2021
Ola Landgren, MD, PhD, discusses the clinical impact of the 4-drug combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in patients with multiple myeloma.